Arkolith/Insider Trading/RCUS/Form 4

Goeltz II Robert C.

Chief Financial OfficerArcus Biosciences, Inc. (RCUS) · full profile →Form 4 · filed Jan 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$153K
Net Open-Market Flow
-$153K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2025Sell(S)7K$23.38$153K68K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML